- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00160849
Lopinavir/r Monotherapy as Maintenance Therapy After Long Term Viral Suppression
Study on the Feasibility of Antiretroviral Therapy With a Single Agent - Lopinavir/r - in Patients Treated With HAART and With Viral Load Below 80 Copies/Ml
Objectives Primary
- To investigate the possibility of maintaining virological suppression of HIV in infected patients, switching them to LPV/r as the only antiretroviral agent
- To assess the immunological response in patients who switched to LPV/r as single agent, based on the observation of changes in the serum levels of CD4+ cells.
Secondary
- To investigate the rate of clinical and laboratorial adverse events in the two treatment groups.
- To investigate the rate of emergence of antiretroviral resistance mutations in the two treatment groups, in case of virological failure of the current regimen.
- To describe the adherence to the prescribed regimen in the two treatment groups
- To describe changes in body fat distribution (abdominal, arms and thigh circumference) and in the lipid profile, in patients from the two treatment groups
- To describe the rate of clinical failure of the antiretroviral therapy in the two treatment groups.
Patient population:
The 60 patients were selected by the investigators according to the study's inclusion and exclusion criteria, and were divided into 2 groups with 30 patients each.
Study design:
The study is multicentric, open-label, randomized. Virological, immunological and clinical failures will be analyzed in both groups. In addition, data on clinical or laboratorial toxicity and compliance are being recorded.
Regime:
- Group 1 maintenance of the currently used antiretroviral therapy
- Group 2 switch to LPV/r antiretroviral monotherapy in the dose of 400/100 mg 12/12 hs with food. Patients in group 2 who were being treated previously with non-nucleoside reverse transcriptase inhibitors (Efavirenz or Nevirapine) were instructed to take 4 capsules of Lopinavir/r each 12 hs, during the first 14 days of therapy (up to Week 2 visit).
- Duration:
96 weeks of treatment
Study Overview
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20210.030
- Projeto Praca Onze
-
-
Rio de Janeiro
-
Nova Iguaçu, Rio de Janeiro, Brazil, 01620.020
- Hospital Geral de Nova Iguaçu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patients must fulfill all of the following criteria: The patient has confirmed his/her willingness to participate in the study, after being informed about all the aspects of the study that might be relevant for his/her decision to participate, and has signed and dated the informed consent form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC). And he/she can withdraw the study participation at any moment, if he/she wants to do so.
- The patient has laboratorial confirmation of an HIV infection through a positive ELISA test for anti-HIV antibodies and an additional test (Western-blot, indirect immunofluorescence or PCR).
- The patient must be in treatment with at least three antiretroviral drugs, for at least 6 months without changes.
- The patient should have no history of documented virological failure to previously used antiretroviral therapies.
- Undetectable viral load (test result < 400 copies/ml) for more than 6 months measured on a sample collected during treatment with the current regimen and at screening (test result < 80 copies).
- CD4 count > 200 cels/ml at screening
- Patient agrees not to use concomitant medication that might have unacceptable drug interactions with the study drug.
- If the patient is a female, she must have a negative pregnancy test and must agree to use at least 14 days before the study drug administration and for the whole study duration and up to 6 months after, a barrier contraceptive method with a proven reliability track record, as judged by the investigator
Exclusion Criteria:
- Pregnant or lactating female patient. If the patient becomes pregnant during the study, she will be discontinued from the study.
- Patients with allergic reaction or hypersensitivity to Lopinavir or Ritonavir .
- A patient with previous history of opportunistic disease ( appendix 1) or CD4 count below 100 cels/mm3.
- A patient who presents any HIV viral load test result above 400 copies/mL over the past 6 months.
- Patient who is receiving or has received systemic chemotherapy during the past 6 months.
- Laboratory test results Hemoglobin < 8 g/dl Absolute neutrophil count < 750 cels/mL Platelet count < 20,000/mL Bilirubin > 1.5 x UNL or > 6 x UNL if patient is using Indinavir or Atazanavir ALT and AST > 2 x UNL Creatinine > 2 x UNL
- Patient is taking any drug known to be contraindicated concomitantly with lopinavir/r. Please refer to the product's package insert.
- According to the investigator's opinion, the patient has little probability of complying with the study protocol or is unsuitable for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
• Rate of suppression of viral load to less than 80 copies/ml on weeks 4, 12, 24, 36, 48, 60, 72, 84, 96.
|
• Average change of CD4 count on weeks 4, 12, 24, 36, 48, 60, 72, 84, 96
|
• Two-year incidence rate of immunodeficiency related clinical conditions.
|
Secondary Outcome Measures
Outcome Measure |
---|
• Toxicity rate (clinical and laboratorial adverse events).
|
Collaborators and Investigators
Investigators
- Principal Investigator: Estevão P Nunes, M.Sc, Projeto Praca Onze
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Lopinavir
Other Study ID Numbers
- KalMo
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Lopinavir/r
-
University of LiverpoolJanssen Pharmaceutica; Yaounde Central Hospital; Chantal Biya International Reference...Completed
-
Willem Daniel Francois VenterMedical Research Council, South AfricaCompleted
-
University of California, San DiegoAbbottCompletedHIV InfectionUnited States
-
AbbottCompleted
-
ANRS, Emerging Infectious DiseasesJanssen PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIVUnited States, South Africa, Thailand, Brazil
-
University of California, Los AngelesUniversity of Colorado, Denver; National Institute of Allergy and Infectious... and other collaboratorsCompletedRNA Virus Infections | Respiratory Tract Infections | Influenza, Human | Orthomyxoviridae Infections | Respiratory Tract Disease | Virus Disease | Physiological Effects of Drugs | VaccinesUnited States
-
The HIV Netherlands Australia Thailand Research...Roche for trial and Saquinavir,and Abbott for KaletraCompleted
-
Klinikum NürnbergUnknown
-
Case Comprehensive Cancer CenterTerminatedGlioblastoma | Brain Tumor | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Giant Cell Glioblastoma | Mixed Glioma | Brain Stem GliomaUnited States